Pfizer has cut roughly 2,000 employees globally in a multi-year cost realignment targeting $7 billion in savings. Here is what your pharma and regulatory expertise is worth independently.

Pfizer announced its multi-year cost realignment program in October 2023 and has cut approximately 2,000 employees globally since then. The company is targeting $7 billion in savings by 2027 and has described the reductions as focused on improving R&D productivity and increasing automation and digital enablement. Affected sites include the Seagen oncology headquarters in Bothell, Washington (at least 100 roles), operations in Switzerland (reducing headcount from 300 to approximately 70), and other sites globally.

The broader context matters. Pfizer generated extraordinary revenue from its COVID-19 vaccine and antiviral products in 2021 and 2022, then saw that revenue collapse as the pandemic receded. The company spent heavily on acquisitions, most significantly Seagen for $43 billion, and now faces the challenge of integrating those assets while managing a significantly changed revenue picture. The cuts are partly structural rebalancing after a period of exceptional (and non-recurring) growth.

Pfizer's portfolio is large and commercially significant: oncology (expanded significantly through Seagen), vaccines, specialty medicines, and hospital drugs. The professionals being cut have worked on some of the most commercially important pharmaceutical products in the world. That experience, in clinical development, regulatory affairs, commercial launch, and market access, is in active demand from the broader biopharmaceutical industry.

‍

Pfizer alumni are among the most sought-after advisors in pharmaceutical consulting. The company's scale, regulatory rigor, and commercial discipline mean that its practitioners are trusted to operate at a level that smaller biotech and specialty pharma companies aspire to reach.

Medical affairs and regulatory affairs directors from Pfizer typically bill $200 to $400 per hour working independently. Oncology commercial and market access specialists, particularly those with Seagen's targeted therapy expertise, are in extremely high demand from the growing pipeline of oncology biotechs preparing for launch. Retainer engagements for oncology launch advisory typically run $15,000 to $30,000 per month. Clinical trial operations managers with Pfizer's multi-country trial infrastructure experience are sought by CROs and emerging biotech sponsors at $175 to $325 per hour.

Digital and R&D productivity specialists, people who worked on Pfizer's automation and AI-enhanced drug development programs, are in demand from pharmaceutical companies trying to build similar capabilities. This is a newer but fast-growing advisory category with rates starting at $200 per hour for experienced practitioners.

‍

Pfizer directors and senior managers typically earned $175,000 to $340,000 in total compensation. Medical affairs and regulatory directors often reached $300,000 to $450,000, reflecting the specialized expertise and regulatory responsibility those roles carry. The severance packages offered as part of the multi-year cost realignment program are generally structured to provide several months of financial runway.

To set a consulting rate: if your gross revenue goal is $280,000 (netting approximately $200,000 after taxes and benefits), divide by 1,000 expected billable hours for a $280 per hour target. For medical affairs, regulatory, and oncology specialists, the market will support $300 to $425 per hour from the outset given the demand and scarcity of experienced practitioners. Anchor your rate at the appropriate market level rather than discounting to get your first client faster.

In pharmaceutical consulting, much of the work is structured as project-based or retainer engagements rather than hourly billing. A regulatory advisory engagement for an FDA submission might be a $60,000 to $100,000 project. Thinking in terms of project scope and value will serve you better than pure hourly rate calculations in this market.

‍

Pfizer built your professional credibility at one of the most scrutinized companies in the world. The COVID-19 vaccine experience, regardless of which function you worked in, added a layer of public visibility and operational complexity to your professional record that very few pharmaceutical professionals anywhere can match.

The positioning for most Pfizer alumni is built around therapeutic area depth and regulatory or commercial function. "I help oncology biotechs build the regulatory and medical affairs infrastructure they need to prepare their first FDA submission" is a statement that an oncology CMO or CCO will immediately engage with. "I help pharmaceutical companies design digital-enabled clinical trials that reduce cost and timeline without compromising data integrity" speaks to a specific and urgent market.

If you worked on the Seagen integration, you have specific M&A and post-merger integration experience in a complex, high-stakes pharmaceutical environment. That is valuable to private equity firms evaluating pharmaceutical acquisitions, to mid-size pharma companies managing their own integrations, and to investment banks advising on pharma M&A.

Name the problem, name the buyer, and let the Pfizer credential do the credibility work.

‍